The Rx Consultant 

Managing Urinary Incontinence in Older Adults

This CE activity was originally published in The Rx Consultant.  If you received credit for it previously, you cannot receive credit for it again.
Urinary incontinence (UI) is a common condition in older adults. An estimated 30% to 50% of elderly women and 20 to 30% of elderly men are affected. Up to 10% of all nursing home admissions are attributed to UI, and over 50% of nursing home residents have UI. Incontinence can have a profound effect on well-being and quality of life; sufferers often experience social isolation, anxiety, depression, impaired sexual relationships, insomnia (if nocturia occurs), and an increased risk of falls and fractures. Other health consequences include urinary tract infections and urosepsis from urinary retention and indwelling catheters, and skin infections and pressure ulcers from constant moisture and irritation. Among community dwelling individuals in the U.S., the total cost of care including evaluation, treatment, home care, and nursing home admission was an estimated $14 billion in 2000.

Despite its impact, UI is underreported by patients, underdetected by clinicians, and undertreated. Embarrassment, a belief among both patients and clinicians that UI is a normal part of aging, and an assumption that not much can be done for UI in older adults are key factors. Community healthcare providers can reduce the impact of UI by informing patients and other clinicians that effective management is attainable.

This issue will present an overview of UI and the recommended, stepwise approach for managing the most common types in older adults. This issue will review the medications used for the treatment of urge UI and overactive bladder (OAB), including 6 antimuscarinicantimuscarinic agents and newer medications such as mirabegron (MyrbetriqTM) and onabotulinumtoxinA (BOTOX®). Medications used in the management of stress UI will also be discussed.
This CE activity is a monograph (PDF file).



CE Hours


CE Units


Activity Type


Target Audience(s)

Pharmacists, Nurse Practitioners, Clinical Nurse Specialists, and Registered Nurses


This CE activity was developed by The Rx Consultant, a publication of Continuing Education Network, Inc.

CE activities for Pharmacists and Pharmacy Technicians:
This continuing education (CE) activity meets the requirements of all state boards of pharmacy for approved continuing education hours.  CE credit is automatically reported to CPE Monitor.
CE activities for Nurse Practitioners and Clinical Nurse Specialists: 
    This continuing education activity meets the requirements of:
        The American Nurses Credentialing Center (ANCC) for formally approved continuing education (CE) hours, and CE hours of pharmacotherapeutics.
        The American Academy of Nurse Practitioners Certification Program (AANPCP) for acceptable, accredited CE.
    This is a pharmacotherapeutics/pharmacology CE activity.
  • The ANCC requires all advanced practice nursing certificants (CNSs and NPs) to complete 25 CE hours of pharmacotherapeutics as a portion of the required 75 continuing education hours.
  • Pharmacology CE is recommended by the AANPCP and will be required for Certificants renewing certification starting January 2017.  
  • Most State Boards of Nursing require a minimum number of pharmacy contact hours to renew an advanced practice license.
Accreditation Council for Pharmacy Education
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Requirements for CE Credit

CE No Longer Valid
To receive CE credit, the participant must read the monograph in its entirety, complete the online post-test and receive a score of 70% or greater, and complete the online evaluation.
Pharmacists and Pharmacy Technicians -
Be sure your profile has been updated with your NAPB e-profile # and birth date information BEFORE completing the online evaluation, or your credits cannot be reported to CPE Monitor.
Continuing pharmacy education credit is automatically reported to CPE Monitor once the post-test & evaluation are successfully completed.




  • Explain non-drug measures than can minimize the need for or intensity of drug therapy for urinary incontinence (UI).
  • Describe the symptoms and prevalence of urge, stress and mixed UI. List 2 myths about UI in older adults.
  • Indicate key drug therapies for each type of UI and overactive bladder syndrome.
  • Describe the common and serious side effects of antimuscarinic agents. Counsel patients about side effects, including self-management and when to seek prompt medical attention.


Pamela Mausner, MD

Brief Bio : Pamela Mausner, MD; Medical Writer/Editor and Healthcare Advocate; and Associate Editor, The Rx Consultant.
Disclosure : Dr.Mausner reports no financial relationship with the manufacturer(s) or provider(s) of any commercial product(s) or service(s) that appear in this issue.

Thomas E. Lackner, PharmD, CGP, FASCP

Brief Bio : Thomas E. Lackner, PharmD, CGP, FASCP, Director of Pharmacy Services, Univita Health
Disclosure : Dr. Lackner reports no financial or personal relationship with any commercial interest producing, marketing, reselling, or distributing a product or service that appears in this issue.

Tracy Farnen, PharmD

Brief Bio : Tracy Farnen, PharmD; Managing Editor, The Rx Consultant.
Disclosure : Dr. Farnen reports no financial relationship with the manufacturer(s) or provider(s) of any commercial product(s) or service(s) that appear in this issue.

Activity Number


Release Date: Jan 18, 2013
Credit Expiration Date: Jan 18, 2016

CE Hours